Serum inhibin A, VEGF and TNFα levels after triggering oocyte maturation with GnRH agonist compared with HCG in women with polycystic ovaries undergoing IVF treatment: a prospective randomized trial
Open Access
- 26 January 2006
- journal article
- research article
- Published by Oxford University Press (OUP) in Human Reproduction
- Vol. 21 (5) , 1260-1265
- https://doi.org/10.1093/humrep/dei475
Abstract
BACKGROUND: We aimed to examine the serum levels of inhibin A, vascular endothelial growth factor (VEGF), tumour necrosis factor α (TNFα), estradiol (E2) and progesterone levels after triggering of final oocyte maturation with GnRH agonist compared with HCG in patients with polycystic ovaries (PCO) and to investigate the relationship between these markers and ovarian hyperstimulation syndrome (OHSS). METHODS: Twenty-eight patients with PCO, undergoing controlled ovarian hyperstimulation with FSH and GnRH antagonist for IVF–embryo transfer treatment, were randomized for triggering of final oocyte maturation with GnRH agonist (GnRH agonist group, n = 15) or HCG (HCG group, n = 13). Blood samples were obtained on the day of randomization and thereafter every 2–7 days. Serum levels of inhibin A, VEGF, TNFα, E2 and progesterone, the incidence of OHSS, ovarian size and pelvic fluid accumulation were evaluated. RESULTS: Serum inhibin A, E2 and progesterone levels were significantly lower in the GnRH agonist group compared with the HCG group, particularly on the day of embryo transfer (P < 0.0001). Serum VEGF and TNFα levels were similar between the two groups. Four patients in the HCG group developed severe OHSS, whereas no patient had any symptoms or signs of OHSS in the GnRH-agonist group (P < 0.05). CONCLUSIONS: In patients with PCO treated with FSH/GnRH antagonist, final oocyte maturation with GnRH agonist instead of HCG reduces significantly inhibin A, E2 and progesterone levels during the luteal phase. This phenomenon reflects the inhibition of the corpus luteum function and may explain, at least in part, the mechanism of OHSS prevention in high-risk patients. Our results do not support a crucial role for VEGF or TNFα in OHSS.Keywords
This publication has 43 references indexed in Scilit:
- Nonsupplemented Luteal Phase Characteristics after the Administration of Recombinant Human Chorionic Gonadotropin, Recombinant Luteinizing Hormone, or Gonadotropin-Releasing Hormone (GnRH) Agonist to Induce Final Oocyte Maturation inin VitroFertilization Patients after Ovarian Stimulation with Recombinant Follicle-Stimulating Hormone and GnRH Antagonist CotreatmentJournal of Clinical Endocrinology & Metabolism, 2003
- Ovarian hyperstimulation syndrome: classifications and critical analysis of preventive measuresHuman Reproduction Update, 2003
- Concentration of vascular endothelial growth factor released by cultured human luteinized granulosa cells is higher in women with polycystic ovaries than in women with normal ovariesFertility and Sterility, 2002
- GnRH antagonist in assisted reproduction: a Cochrane reviewHuman Reproduction, 2002
- Prognostic importance of serial cytokine changes in ascites and pleural effusion in women with severe ovarian hyperstimulation syndromeFertility and Sterility, 1999
- Variations in peripheral blood levels of immunoreactive tumor necrosis factor α (TNFα) throughout the menstrual cycle and secretion of TNFα from the human corpus luteumEuropean Journal of Obstetrics & Gynecology and Reproductive Biology, 1999
- Serum vascular endothelial growth factor (VEGF) in the normal menstrual cycle: association with changes in ovarian and uterine Doppler blood flowClinical Endocrinology, 1999
- Endocrinology: Plasma inflammatory cytokines correlate to the ovarian hyperstimulation syndromeHuman Reproduction, 1996
- Diagnosis, prevention and management of ovarian hyperstimulation syndromeBJOG: An International Journal of Obstetrics and Gynaecology, 1995
- MULTIFOLLICULAR OVARIES: CLINICAL AND ENDOCRINE FEATURES AND RESPONSE TO PULSATILE GONADOTROPIN RELEASING HORMONEThe Lancet, 1985